360° SearchNetwork Hot Spots Trends Time Series

second-line therapy

Type: Keyphrase

Name: second-line therapy

First reported Jun 10 2013 - Updated Jun 10 2013 - 1 reports

NCCN 18th Annual Conference: Advancing the Standards of Cancer Care

At the 18th Annual Conference of the National Comprehensive Cancer Network (NCCN), experts presented the latest updates to the NCCN Clinical Practice Guidelines in Oncology. The conference also featured two roundtable discussions that covered topics including ... [Published OncLive - Jun 10 2013]

Entities: bevacizumab, guidelines, Tumor, Patient, Cancer

First reported Jun 08 2013 - Updated Jun 08 2013 - 1 reports

Livestream

Seven group benefits experts hold virtual counsel on how they’re using technology in the group provider spaceJean-François Chalifoux, senior vice-president, group business insurance, Desjardins Financial Security Brad Fedorchuk, vice-president, group ... [Published Benefits Canada - Jun 08 2013]

Entities: Internet Fraud, Great-West Life Assurance Company, Invention, Adjudication

First reported Jun 06 2013 - Updated Jun 06 2013 - 1 reports

New UK lung cancer survey goes 'live'

LATEST : ASCO 2013 - Latest news and videos ASCO 2013 - Latest news and videos Register now for the 2013 WIN Symposium, ecancer members receive a 10% discount Announcing the 2nd Summer School in Computational Oncology News: News: ASCO 2013: Two commonly ... [Published Ecancer Medicalscience - Jun 06 2013]

Entities: Lung Cancer, United Kingdom, Paclitaxel Chemotherapy

First reported Jun 06 2013 - Updated Jun 06 2013 - 1 reports

Research and Markets Adds Report: Tasigna (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022

Research and Markets has announced the addition of the "Tasigna (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022" report to its offerings.In a release, Research and Markets noted that report highlights include:Chronic myeloid leukemia ... [Published Individual.com - Jun 06 2013]

Entities: Tasigna, chronic myeloid leukemia, market analysis, Nilotinib, second-line therapy

First reported Jun 05 2013 - Updated Jun 05 2013 - 1 reports

Surgery Options for Obstructive Sleep Apnea

Going Under the Knife to Treat Sleep Apnea When CPAP Fails For those who are unable to tolerate continuous positive airway pressure (CPAP) to treat their obstructive sleep apnea (OSA), what surgery options exist? There are a handful, but they may be of ... [Published About - Jun 05 2013]

Entities: Obstructive Sleep Apnea, Airway, Tracheotomy, Apnea, Trachea

First reported Jun 05 2013 - Updated Jun 05 2013 - 1 reports

Alternative Treatments for Sleep Apnea

From Weight Loss to Surgery, Potential Fixes Abound If you have been diagnosed with sleep apnea, the first treatment option offered will likely be continuous positive airway pressure (CPAP), but what if you need alternative treatments for your sleep apnea? ... [Published About - Jun 05 2013]

Entities: Sleep Apnea, Airway, Apnea, Snoring

First reported Jun 03 2013 - Updated Jun 04 2013 - 2 reports

ASCO: GALAXY-2 'Proof of Principle' in Lung Ca Tx

Note that this study was published as an abstract and presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.Ganetespib, a heat shock protein 90 inhibitor, in combination ... [Published MedPage Today - Jun 03 2013]

Entities: Docetaxel, Ganetespib, adenocarcinoma, progression-free survival

First reported May 31 2013 - Updated Jun 01 2013 - 1 reports

GSK eyes first-line use for leukaemia drug Arzerra

Positive phase III trial results back regulatory filings for earlier useGlaxoSmithKline (GSK) has said it will file for approval of its chronic lymphocytic leukaemia (CLL) therapy Arzerra as a first-line therapy on the back of positive phase III trial ... [Published PMLive - May 31 2013]

Entities: Arzerra, Leukaemia, Drugs

First reported May 26 2013 - Updated May 26 2013 - 1 reports

An unpredictable disease

An early diagnosis for multiple sclerosis can be easily missed as it is a rare disease and symptoms can sometimes be non-specific or mimic other more common medical conditions.SHARIFAH was 18 years old when she was diagnosed with multiple sclerosis (MS). ... [Published thestar.com.my - May 26 2013]

Entities: Multiple Sclerosis, myelin, Neuron

First reported May 23 2013 - Updated May 23 2013 - 1 reports

Axitinib in metastatic renal cell carcinoma: Results of a pharmacokinetic and pharmacodynamic analysis - Abstract

Axitinib is a potent and selective inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, approved for second-line therapy for advanced renal cell carcinoma (RCC).Tags:SearchComments (0)Only registered users can write comments!Powered ... [Published UroToday - May 23 2013]

Entities: Axitinib, renal cell carcinoma, Pharmacokinetics, Metastatic

First reported May 23 2013 - Updated May 23 2013 - 1 reports

Transient Sunitinib Resistance in Gastrointestinal Stromal Tumors

To the Editor: Sunitinib — an oral tyrosine kinase inhibitor targeting KIT, platelet-derived growth factor receptors α and β, vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3, and other receptors — is an effective second-line therapy for ... [Published The New England Journal of Medicine: Hematology ... - May 23 2013]

Entities: Sunitinib, gastrointestinal, Transient, Receptor

First reported May 22 2013 - Updated May 22 2013 - 1 reports

Comment A new approach to secondline therapy for urothelial cancer

Home » Articles » [Comment] A new approach to second-line therapy for urothelial cancer?Despite responses shown by 40–60% of patients with advanced urothelial carcinoma receiving first-line cisplatin-based combination chemotherapy, disease progression ... [Published BioPortfolio - May 22 2013]

Entities: second-line therapy, Cancer, combination chemotherapy, Biotechnology

Quotes

...According to news reporting originating from Seattle, Washington, by NewsRx correspondents, research stated, "Protease inhibitor (PI)-based antiretroviral therapy (ART) can effectively suppress HIV-2 plasma load and increase CD4 counts; however, not all PIs are equally active against HIV-2, and few data exist to support second-line therapy decisions. To identify therapeutic options for HIV-2 patients failing ART, we evaluated the frequency of PI resistance-associated amino acid changes in HIV-2 sequences from a... We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3."

Recent Findings from University of Washington Advance Knowledge in HIV/AIDS [Published NewsRX - Jun 15 2013]

"The paper explores various strategies and suggests cost-effective options for HIV testing in India," Swaminathan said. "As India moves ahead in its HIV prevention activities and aims for zero new infections, expanding testing will be a key priority and this analysis should help policymakers make the best decisions."

Study explores various strategies, suggests cost-effective options for HIV testing in India [Published News-Medical.Net - Jun 11 2013]

"With the background wave on test and treat, this article will be a useful scientific tool for the National AIDS Control Organization of India to plan the testing strategies nationwide" he said. In addition to Venkatesh, Becker, Swaminathan, and Kumarasamy, other authors are Yoriko Nakamura, Dr. Kenneth Mayer, Elena Losina, Dr...

Cost-effective: Universal HIV testing in India [Published EurekAlert! - Jun 10 2013]

"This is a first-in-class study showing the potential efficacy of this compound, and I think it presents a potential advance in an area of lung cancer where we haven’t had advances in a long time, and we’re all eagerly awaiting the outcome of the phase III trial" said Dr. Marjorie Zauderer, a medical oncologist and lung cancer specialist at Memorial Sloan-Kettering Cancer CenterSloan-Kettering Cancer Center New...

Ganetespib trial hints at survival benefit in lung adenocarcinoma [Published Oncology Report - Jun 05 2013]

More Content

sort by: Date \| Relevance
Use of Natalizumab in Patients with Active Rela... [Published Sexual Development - 12 hours ago]
Crizotinib Improves Progression-Free Survival i... [Published National Cancer Institute - 17 hours ago]
Cancer Pain Eased by MR-Guided, Focused Ultraso... [Published MedImaging.net - 20 hours ago]
Postmenopausal Hormone Receptor–Positive Advanc... [Published Cancernetwork.com - Jun 18 2013]
Recent Findings from University of Washington A... [Published NewsRX - Jun 15 2013]
ASCO: Cetuximab Ups Survival Over Bevacizumab i... [Published Cancernetwork.com - Jun 14 2013]
Studies Highlight Advances in Lung and Breast C... [Published American Society of Clinical Oncology - Jun 14 2013]
Novartis: Drug Pipeline And New Drug Applications [Published Seeking Alpha - Jun 13 2013]
Renewable Energy Stock Alert: Ceres (CERE) Foll... [Published InvestorIdeas.com - Jun 13 2013]
Oral Lichen Planus [Published Advance for NPs and PAs - Jun 11 2013]
Leading Oncologists Analyze Impact of New HER2 ... [Published OncLive - Jun 11 2013]
Study explores various strategies, suggests cos... [Published News-Medical.Net - Jun 11 2013]
Resisting Drug Resistance in Resource-Constrain... [Published AIDS Clinical Care - Jun 11 2013]
NCCN 18th Annual Conference: Advancing the Stan... [Published OncLive - Jun 10 2013]
Cost-effective: Universal HIV testing in India [Published EurekAlert! - Jun 10 2013]
Winners And Losers in CLL at ASCO '13 [Published Berks-Mont News - Jun 10 2013]
Livestream [Published Benefits Canada - Jun 08 2013]
This Week in Blood: June 7, 2013 [Published American Society of Hematology - Jun 07 2013]
Proteomic Stratification Test Can Help Guide Se... [Published Cancernetwork.com - Jun 06 2013]
New UK lung cancer survey goes 'live' [Published Ecancer Medicalscience - Jun 06 2013]
Research and Markets Adds Report: Tasigna (Chro... [Published Individual.com - Jun 06 2013]
Ganetespib Promising for Advanced Lung Cancer [Published CancerConnect.com - Jun 06 2013]
Alternative Treatments for Sleep Apnea [Published About - Jun 05 2013]
Surgery Options for Obstructive Sleep Apnea [Published About - Jun 05 2013]
Ganetespib trial hints at survival benefit in l... [Published Oncology Report - Jun 05 2013]
AstraZeneca drops arthritis candidate fostamatinib [Published PMLive - Jun 04 2013]
Can Second-Generation ALK Inhibitors Outshine X... [Published Oncology Business Review - Jun 04 2013]
ASCO: GALAXY-2 'Proof of Principle' in Lung Ca Tx [Published MedPage Today - Jun 03 2013]
ASCO 2013: Novel drug that inhibits Hsp90 effec... [Published Ecancer Medicalscience - Jun 03 2013]
Cancer Drug Developers Report Latest Phase III ... [Published Pharma-Mag - Jun 03 2013]

Blogs

sort by: Date \| Relevance
Cancer Drug Developers Report Latest Phase III ... [Published Pharma-Mag - Jun 03 2013] Synta, Novartis, Lilly, Roche, and the latter’s biotech business Genentech report Phase III trial data at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO). Synta Pharmaceuticals reported positive data from the ongoing ...
InPlay from Briefing.com [Published MaritimeSecurity.Asia - Feb 13 2013] 7:02 pm Limoneira announces the annexation of East Area 1 into the city of Santa Paula ( LMNR ) : Co announced that on February 12, 2013, East Area 1 was formally annexed into Santa Paula. The annexation was the final required step to enable Limoneira ...

Press Releases

sort by: Date \| Relevance
Synta Announces Presentations at the 2013 Ameri... [Published Business Wire Science: Science News - May 15 2013]
Synta Announces Presentations at the 2013 Ameri... [Published Business Wire Health News - May 15 2013]
OncoGenex Announces Plans for the Initiation of... [Published PR Newswire: Health - Feb 12 2013]